What is the recommended temperature monitoring and management protocol for a child after cardiac arrest?

Post-Cardiac Arrest Temperature Monitoring in Children

For comatose children after cardiac arrest, continuously monitor core temperature and maintain targeted temperature management (TTM) at ≤37.5°C for at least 24-72 hours to prevent fever, which is strongly associated with worse neurologic outcomes and mortality. 1, 2

Core Temperature Monitoring Protocol

Continuous core temperature monitoring is essential using one of these reliable sites 2:

• Esophageal (most accurate during active cooling)
• Bladder (practical for continuous monitoring)
• Rectal (acceptable alternative)

Avoid intermittent tympanic measurements—they are unreliable for precise temperature control 3.

Temperature Target Selection

The 2020 ILCOR guidelines updated the 2015 recommendations with a more conservative approach 1:

Primary recommendation: Maintain central temperature ≤37.5°C (weak recommendation, moderate-certainty evidence)

Optional strategies based on institutional protocols:

• Hypothermia: 32-34°C
• Normothermia: 36-37.5°C

The 2025 AHA guidelines emphasize that preventing hyperthermia is the critical priority, with optional use of structured temperature control protocols 2, 4. The landmark THAPCA trials showed no significant difference in neurologic outcomes between 33°C versus 36.8°C targets, but both actively prevented fever 5.

Duration of Temperature Management

Minimum 24 hours, optimally 36-72 hours of active temperature control 5, 1:

• The THAPCA trials used 5 days of continuous monitoring with 72 hours of active TTM 2
• Fever occurring even after initial 24-hour period correlates with poor outcomes 6
• Continue fever prevention throughout the recovery phase (up to 7 days) 5

Implementation Algorithm

Immediate Phase (0-20 minutes post-ROSC):

1. Establish continuous core temperature monitoring
2. Begin active cooling if temperature >37.5°C
3. Document baseline temperature

Early Phase (20 minutes to 12 hours):

1. Select target temperature (institutional protocol: 32-34°C or 36-37.5°C)
2. Initiate cooling method:
   • Servo-controlled cooling blankets (preferred—more effective at maintaining target) 7
   • Ice packs to groin, axillae, neck
   • Cold IV crystalloid (30 mL/kg at 4°C) if rapid cooling needed 3
3. Prevent shivering: Use sedation ± neuromuscular blockade 3

Maintenance Phase (12-72 hours):

1. Maintain target temperature within ±0.5°C
2. Monitor for complications:
   • Arrhythmias (risk increases if <32°C)
   • Coagulopathy
   • Infection
   • Electrolyte disturbances
3. Scheduled antipyretics if using normothermic target 8

Rewarming Phase (if hypothermia used):

Slow, controlled rewarming at 0.25-0.5°C per hour 6:

• Avoid rapid rewarming (>0.5°C/hour)—associated with worse outcomes
• Prevent rebound hyperthermia
• Continue monitoring for 24-48 hours post-rewarming

Critical Pitfalls to Avoid

Fever is the enemy: Even brief episodes of hyperthermia (>38°C) correlate with increased mortality in both IHCA and OHCA 2, 9. A quality improvement study showed that implementing a TTM bundle reduced fever time from 7% to 0% (p<0.001) 8.

Passive temperature management is inadequate: Compared to servo-controlled systems, passive management resulted in 60% fever incidence versus 10% with homeothermic blankets (NNT=2 to prevent one fever) 9.

Don't overcool: Temperatures <32°C increase complications without additional benefit 3. The evidence does not support deeper hypothermia.

Uncontrolled rewarming is harmful: Spontaneous hypothermia on presentation may indicate severe injury—these patients need controlled rewarming, not passive warming 6.

Evidence Quality and Nuances

The evidence base shows moderate-certainty that TTM is feasible and safe, but low-certainty regarding optimal target temperature 1, 10. The THAPCA trials (largest pediatric RCTs with 260-287 patients) found no difference between 33°C versus 36.8°C for the primary outcome, but both groups had active fever prevention 5.

Key distinction by arrest location:

• Out-of-hospital cardiac arrest (OHCA): 2015 guidelines suggest TTM (weak recommendation) 5
• In-hospital cardiac arrest (IHCA): Insufficient evidence for formal recommendation 5

However, the 2020 update applies the ≤37.5°C recommendation to both OHCA and IHCA 1, reflecting that fever prevention benefits all post-arrest children regardless of location.

Recent meta-analysis (2026) of 2,107 pediatric patients showed therapeutic hypothermia associated with improved survival (OR 1.72,95% CI 1.36-2.18) and favorable neurologic outcome (OR 1.64,95% CI 1.16-2.33), though evidence certainty remains low 11.

Practical Implementation

Servo-controlled systems are superior but not mandatory: A multicenter study across 20 centers showed TTM was feasible with both servo-controlled (72.8% of patients) and manual methods, though servo-controlled maintained target temperature more effectively (69% vs 60% time in target, p=0.004) 7. Use available resources but prioritize any method that prevents fever over no temperature control.

System-level approach: The 2025 guidelines emphasize that successful temperature management requires coordinated protocols, trained staff, and continuous quality monitoring 2, 12, 4.